Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen
Colorized scanning electron micrograph of mpox virus particles (blue) on the surface of infected VERO E6 cells (pink). NIAID A dose-sparing intradermal mpox vaccination regimen was safe and generated an…
A vaccine to fight antibiotic resistance
Driven by the overuse of antimicrobials, pathogens are quickly building up resistances to once-successful treatments. It’s estimated that antimicrobial-resistant infections killed more than 1 million people worldwide in 2019, according…
mRna, MD Anderson and CureVac enter strategic collaboration to develop novel cancer vaccines
The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines. The collaboration creates strong synergies between…
CDC updates and simplifies respiratory virus recommendations
CDC released today updated recommendations for how people can protect themselves and their communities from respiratory viruses, including COVID-19. The new guidance brings a unified approach to addressing risks from…